Note: Descriptions are shown in the official language in which they were submitted.
=
CA 02564982 2006-10-27
1
PEGYLATED NANOPARTICLES
FIELD OF THE INVENTION
The invention relates to pegylated nanoparticles based
on a biodegradable polymer and a polyethylene glycol, with
process for manufacturing same with formulations containing
them and their use as drug administration systems.
BACKGROUND OF THE INVENTION
In recent years biodegradable polymeric nanoparticles
have been proposed as new drug administration systems. One of
the most important features that they offer is the controlled
release of the incorporated drug. This leads to greater
therapeutic efficacy, provides a more
comfortable
administration for the patient and allows preventing overdose.
Furthermore, drugs with different physicochemical features can
be included, enabling improving their stability in biological
fluids. This fact is very important in the case of antigens,
proteins and macromolecules in general. Furthermore due to
their small size, nanoparticles are suitable for the
administration of drugs through various routes, such as
orally, parenterally and ocularly (Kreuter, Adv. Drug Del.
Rev., 7 (1991) 71-86; Gref et al., Science, 263 (1994) 1600-
1603; Zimmer and Kreuter, Adv. Drug Del. Rev., 16 (1995) 61-
73).
Oral administration is the most convenient and popular
route for the administration of drugs. However, the
bioavailability of a certain active molecule depends (i) on
the characteristics of the molecule of the drug and on the
pharmaceutical form and (ii) on the physiological conditions
present in the gastrointestinal tract, such as the presence of
proteolytic enzymes, peristaltic movements and presystemic
metabolism. Colloidal systems such as nanoparticles have been
proposed to overcome some of these obstacles. These carriers
essentially have a large specific surface whereby their
interaction with the biological support (gastrointestinal
CA 02564982 2006-10-27
2
mucosa) is facilitated. The drug release control also allows
prolonging over time the effect of molecules with low
biological half-lives. On the other hand, nanoparticles can be
uptaken by Peyer's patch cells and by lymphoid tissue
follicles (Hodges et al., J. Drug Target., 3 (1995) 57-60;
Florence, Pharm. Res., 14 (1997) 259-266). This phenomenon
allows directing the drug towards the lymphatic pathway, and
in the case of vaccines facilitating their antigen
presentation. However, conventional nanoparticles have several
significant drawbacks with respect to their use by oral
administration: (i) certain instability in gastrointestinal
fluids, (ii) a low degree of intestinal absorption, and (iii)
non-specific tropism or adhesion in the gastrointestinal
mucosa.
Parenteral administration of nanoparticles provides
controlled systemic release that is suitable for drugs with
(i) low oral bioavailability, (ii) short biological plasma
half-life and (iii) limited stability. Another significant
advantage of parenteral nanoparticles is the possibility of
concentrating the drug in a certain organ. However,
nanoparticles are quickly recognized, uptaken and eliminated
from the blood circulation by macrophages of the mononuclear
phagocyte system (MPS) after their intravenous administration.
This phenomenon limits their function in controlled release as
well as the possibility of concentrating the drug in tissues
other then MPS.
Ophthalmic administration of controlled release systems
has significant advantages for the treatment of ocular
diseases, although a systemic effect may also be obtained.
However, ocular administration is associated to the quick
elimination of the formulation from the precorneal area due to
draining towards the nasolacrimal duct and lacrimal dilution.
These processes give rise to the fact that a very low
percentage of the administered drug may penetrate the cornea
and reach intraocular tissues (less than 5%). This draining is
CA 02564982 2006-10-27
3
responsible for the occurrence of systemic effects upon
administering the formulation through this route. A number of
studies have demonstrated that the use of nanoparticles allows
increasing the amount of the drug in the conjunctiva and
increasing their bioavailability compared with conventional
ophthalmic forms such as solutions and ointments (Gurny et
al., J. Controlled Rel., 6 (1987) 367-373; Deshpande et al.,
Crit. Rev. Ther. Drug Carrier Syst., 15 (1998) 381-420).
Colloidal systems can be administered as simple drops avoiding
vision problems due to their low viscosity. The frequency of
use may be reduced due to the sustained release of the drug
from the matrix of the nanoparticles. However, nanoparticles
also show a quick elimination from the absorption site.
Therefore, even though nanoparticles are potentially
useful for the various previously mentioned administration
methods, there are still problems which make their use
difficult. Modification of the characteristics of the
polymeric matrix as well as of their surface may provide the
solution to some of the problems described above.
From this point of view, the association or coating of
nanoparticles with suitable polymers may modify their
physicochemical characteristics, and it may indirectly modify
their distribution and interaction with the biological medium.
possible strategy is polyethylene glycol (PEG) binding to
the nanoparticles, known as pegylation or obtaining stealthy
nanoparticles.
With respect to their use by oral administration, the
association of polyethylene glycols to conventional
nanoparticles allows protecting them against enzymatic attack
in digestive fluids. This is because of the potential of
polyethylene glycols to reject proteins (Gref et al., Science,
263 (1994) 1600-1603). This strategy would also allow
minimizing their interaction with mucin and other proteins
present in the lumen. A similar strategy has been applied to
the development of the nanoparticles for ocular use. Fresta et
CA 02564982 2006-10-27
4
al. observed a significant increase of the ocular absorption
of acyclovir after its administration in
poly(alkylcyanoacrylate) nanospheres coated with polyethylene
glycol (Fresta et al., J. Pharm. Sci., 90 (2001) 288-297).
This phenomenon is explained by a greater interaction of the
coated nanoparticles with the corneal epithelium.
Various nanoparticles coated with polyethylene glycol
administered intravenously have demonstrated prolonged
circulation (Gref et al., Science, 263 (1994) 1600-1603;
Stolnik et al., Pharm. Res., 11 (1994) 1800-1808; Bazile et
al., J. Pharm. Sci., 84 (1995) 493-498). Poly(lactic) (PLA)
nanoparticles coated with polyethylene glycol have a much
longer plasma half-life = 6
h) than when they are coated
with albumin or poloxamer (t1,2 = 2-3 minutes) (Verrecchia et
al., J. Controlled Rel., 36 (1995) 49-61). The presence of
hydrophilic polyethylene glycol chains on the surface of the
nanoparticles significantly reduces their interaction with
blood proteins (known as opsonins). These proteins promote
phagocytosis forming a "bridge" between the particles and
phagocytes (Frank & Fries, Immunol. Today, 12 (1991) 322-326).
However, the hydrophilic properties of polyethylene glycols
are not the only important factor providing efficient
resistance to opsonization. Other hydrophilic polymers such as
polyvinyl alcohol have demonstrated a low protecting ability
against opsonization of the nanoparticles (Leroux et al., Life
Sci., 57 (1995) 695-703). Therefore, the steric stabilization
provided by pegylation would also be due to other
physicochemical properties, such as the high flexibility of
the PEG chains and a specific structural formation (Mosquiera
et al., Biomaterials, 22 (2001) 2967-2979).
The main drawback with this new strategy is the
stability of the association of polyethylene glycols to the
surface of the nanoparticles (Peracchia et al., Life Sci., 61
(1997) 749-761). It is known that the ability of polyethylene
glycol to reject proteins depends on the configuration, the
CA 02564982 2006-10-27
charge, the length and the flexibility of the chains
(Torchillin, J. Microencaps., 15 (1998) 1-19). The process for
modifying the surface of the nanoparticles is mainly carried
out by physical adsorption (Stolnik et al., Adv. Drug Del.
5 Rev., 16 (1995) 195-214) or by covalent bonding (De Jaeghere
et al., J. Drug Target., 8 (2000) 143-153). However, the
drawback of simple adsorption is the quick loss of the coating
due to the instability of the interaction. Given that covalent
binding is preferable, most pegylated nanoparticles have been
prepared using polyethylene glycol copolymers with lactic or
glycolic acid. However, the copolymerization process requires
the use of several catalysts and specific chemical conditions
(Beletsi et al., Int. J. Pharm., 182 (1999) 187-197).
Furthermore, the toxic organic solvent residues used in the
organic synthesis (methylene chloride, toluene etc.), may be
problematic.
Therefore, it is still necessary to obtain nanoparticles
which are stable in oral administration, which maintain the
hydrophilic coating and which have good bioadhesive
characteristics and specificity in the gastrointestinal tract.
They must be non-toxic, biodegradable and easy to produce in
order to be effective.
SUMMARY OF THE INVENTION
The object of the present invention is to provide
nanoparticles which resolve the previously mentioned
drawbacks, i.e. they have stability and specificity in oral
administration, they have good bioadhesive characteristics for
interacting with mucosae, they are capable of carrying a wide
range of active molecules, they release the active molecule in
a controlled manner and prevent its elimination from the blood
system, especially when they are parenterally administered.
It has been observed that nanoparticles formed by a
biodegradable polymer and polyethylene glycol resolve these
problems. It has especially been found that nanoparticles
formed by a polyvinyl methyl ether and maleic anhydride and
CA 02564982 2006-10-27
6
polyethylene glycol copolymer are easy to produce and provide
excellent bioadhesion, size and zeta potential characteristics
making them suitable for the administration of active
molecules. It has further been found that the selection of the
type of polyethylene glycol used to produce them allows
suitably modulating the features of these nanoparticles, which
can be advantageously used according to the type of drug to be
carried and/or the method of administration of the
pharmaceutical formulation.
Therefore, in a first aspect the invention relates to
pegylated nanoparticles for carrying biologically active
molecules comprising a biodegradable polymer and a
polyethylene glycol or derivatives thereof. In one variant,
the biodegradable polymer is a vinyl methyl ether and maleic
anhydride (PVM/MA) copolymer.
The polyethylene glycol preferably has a molecular
weight comprised between 400 and 35.000 Da. Polyalkylene
glycol provides good results when it is selected from the
group of polyethylene glycols, polypropylene glycols, block or
random copolymers including the two types of units, mixtures
thereof or derivatives thereof. At least one terminal hydroxyl
group of the polyethylene glycol is optionally substituted,
preferably with an alkoxy, acrylate, methacrylate, alkyl,
amino, phosphate, isothiocyanate, sulfhydryl, mercapto or
sulfate group.
In one variant of the invention, the weight ratio
between polyethylene glycol and the biodegradable polymer is
1:2-6, preferably 1:2-4, more preferably about 1:4.
The pegylated nanoparticles of the invention may
incorporate an active molecule, such as proteins, peptides,
DNA, RNA, nucleosides, nucleotides, oligonucleotides or
polynucleotides. In terms of their activity, it may be an
anti-tumor agent or an antigen for tumors, or a protective
agent of the central nervous system or a glucocorticoid, or an
antigen for vaccination or an allergen for immunotherapy,
CA 02564982 2006-10-27
7
among others.
In another aspect, the invention relates to a
pharmaceutical composition comprising pegylated nanoparticles
as described above. In one variant the formulation is for oral
administration. In another variant, it is for parenteral
administration or for administration through mucosa (for
example ophthalmic mucosa).
Therefore, the pegylated nanoparticles of the invention
can be used in the manufacture of a medicament. It can
optionally be in lyophilized form.
In another aspect the invention relates to a process for
preparing pegylated nanoparticles which are described and
comprising the step of simultaneous incubation of the polymer
and the polyethylene glycol in an organic solvent, prior to
desolvating the polymer with a hydroalcoholic solution. In one
variant the concentration of the biodegradable polymer is
comprised between 0.001 and 10% w/v and the concentration of
polyethylene glycol between 0.001 and 5% w/v. The organic
phase/hydroalcoholic solution phase ratio is optionally
comprised in the range between 1/1-1/10.
The process may further comprise additional steps for
eliminating the organic solvents and/or purification, as well
as steps for stabilizing the pegylated nanoparticles by means
of the use of cross-linking agents. The biologically active
molecule can be incorporated in the step of simultaneous
incubation of the polymer and the polyethylene glycol in an
organic solvent, or can subsequently be incorporated in the
aqueous suspension of the already formed nanoparticles so that
their association can occur.
DESCRIPTION OF THE FIGURES
Figure 1 shows transmission electron microscopy (TEN)
photographs of the different types of nanoparticles - (a) NP;
(b) PEG NP; (c) mPEG NP; (d) DAE-PEG NP; (e) DAP-PEG NP. The
scale presents 150 nm.
Figure 2 shows the association of PEG 2000 (mg/mg)
CA 02564982 2006-10-27
8
according to the process used: simultaneous incubation of PEG
and PVM/MA in the organic phase (OP) or incubation of
nanoparticles with the aqueous solution (AP) of the PEG.
Figure 3 shows the effect of the type of polyethylene
glycol on the percentage of PVM/MA converted into
nanoparticles (PVM/MA-e) and on the process yield.
Figure 4 shows nuclear magnetic resonance spectrums of
the pegylated nanoparticles with PEG 2000 (top) and of free
PEG 2000 (bottom). The amplified image of the peak at 4.58 ppm
(protons of the hydroxyl group) is shown in the box.
Figure 5 shows details of the nuclear magnetic resonance
spectrums (a) of the pegylated nanoparticles with PEG 2000 and
(b) of free PEG 2000, dissolved in DMSO (5 mg in 0.5 ml).
Figure 6 shows details of the nuclear magnetic resonance
spectrums (a) of the pegylated nanoparticles with DAP-PEG 2000
and (b) of free DAP-PEG 2000, dissolved in DMSO (5 mg in 0.5
ml).
Figure 7 shows details of the nuclear magnetic resonance
spectrums (a) of the pegylated nanoparticles with DAE-PEG 2000
and (b) of free DAE-PEG 2000, dissolved in DMSO (5 mg in 0.5
ml).
Figure 8 shows structures proposed for the different
pegylated nanoparticles from the nuclear magnetic resonance
data and the zeta potential values - a) PEG-NP; b) mPEG-NP; c)
DAE-PEG-NP; d) DAP-PEG-NP.
Figure 9 shows the distribution of the pegylated
nanoparticles in the gastrointestinal tract after their oral
administration in rats: (a) PEG-NP, (b) mPEG-NP, (c) DAE-PEG-
NP and (d) DAP-PEG-NP. The x-axis represents the amount of
adhered nanoparticles (NP) (mg); the y-axis shows the
different portions of the tract (St: stomach; Il, 12, 13, 14:
intestinal portions; Ce: Cecum; the z-axis represents the time
after the administration (hours).
Figure 10 shows the bioadhesion curves (NP, mg) of the
different pegylated nanoparticles in the entire
CA 02564982 2006-10-27
9
gastrointestinal tract after the oral administration of a
single dose of 10 mg. t: time in hours.
Figure 11 shows fluorescence microscopy images of a
portion of the ileum 2 hours after the oral administration of
10 mg of pegylated nanoparticles with PEG 2000 (PEG-NP). a)
ileum villi: the arrows show the apical compartment of the
epithelium; b) epithelial cells: the arrows show the
fluorescence between the enterocytes. The scale presents 20
m.
Figure 12 shows optical microscopy images of the ileum
segment 2 hours after the oral administration of 10 mg of
pegylated nanoparticles with PEG 2000 (PEG-NP). a) general
view (magnification of 135) and b) enlarged detail
(magnification of 530). L: lumen; E: enterocytes; GC: mucus
generating cells; dark arrows: enterocyte nuclei; white
arrows: blood capillaries in the submucosa.
Figure 13 shows the location of PEG-NP in an ileum
Peyer's patch, two hours after the oral administration of 10
mg of the nanoparticles. a) general view of the Peyer's patch
(magnification of 135); b) enlarged detail (magnification of
530); PP - Peyer's patch; FAE - follicle-associated
epithelium; dark arrows: Peyer's patch dome cells where the
nanoparticles would be included.
DETAILED DESCRIPTION OF THE INVENTION
It has surprisingly been found that the modification and
coating of the nanoparticles of a biodegradable polymer such
as vinyl methyl ether and maleic anhydride (PVM/MA) copolymer
with different polyethylene glycols allows obtaining
nanoparticles with physicochemical, bioadhesion and
specificity characteristics in oral administration converting
them in very interesting systems as special drug carriers. The
features of these nanoparticles can advantageously be
modulated according to the type of polyethylene glycol used
and the preparation process. The pegylated nanoparticles of
the invention can prolong the residence time in the mucosa
CA 02564982 2006-10-27
after their oral or ocular administration. These nanoparticles
are interesting for the administration of drugs with narrow
absorption windows and thus improve their bioavailability.
These nanoparticles are also suitable vectors for drugs with
5 elevated toxicity (for example cytostatic drugs) as they allow
an increase in the plasma circulation time of the system
during which time the drug is gradually released in a
controlled manner. On the other hand, pegylated nanoparticles
can prevent the recognition and elimination by means of
10 mononuclear phagocyte system (MPS) cells, providing a
prolonged circulation of drugs after their intravenous
administration.
The term "nanoparticles" is used to designate spheres or
similar shapes with a size less than 1.0 micrometer,
preferably in the range of 10 to 900 nanometers.
As mentioned above, in one aspect the invention relates
to pegylated nanoparticles formed from a biodegradable
polymer. Biodegradable polymers known in the state of the art
which give rise to the formation of nanoparticles can be used.
These polymers include, among others, polyhydroxy acids such
as polylactic and polyglycolic acid and copolymers thereof
(for example PLGA), polyanhydrides,
polyesters and
polysaccharides, for example chitosan. The
term
"biodegradable" in this description refers to polymers which
dissolve or degrade in a period of time which is acceptable
for the desired application, in this case in vivo therapy,
once they are exposed to a physiological solution of pH 6-9
and a temperature comprised between 25 C and 40 C.
In one variant of the invention vinyl methyl ether and
maleic anhydride copolymer in anhydride form (PVM/MA or
Gantrez AN) is used as the biodegradable polymer. It
preferably has a molecular weight comprised between 100 and
2400 KDa, more preferably between 200 and 2000 KDa. In one
variant of the invention a PVM/MA copolymer with a molecular
weight between 180 and 250 KDa is preferred.
CA 02564982 2013-06-27
n986-8
11
This copolymer is advantageous because it is widely used
in pharmaceutical technology due to its low toxicity (LD 50 =
8-9 g/kg orally) and excellent biocompatibility. It is also
easy to obtain in terms of quantity and its price. This
polymer can react with different hydrophilic substances due to
its anhydride groups without having to resort to the usual
organic reagents (glutaraldehyde and carbodiimide derivatives)
having a significant toxicity (Arbos et al., J. Controlled
Rel., 83 (2002) 321-330). The polymer is insoluble in an
aqueous medium, but the anhydride group of the Gantrez AN
hydrolyzes, giving rise to obtaining carboxylic groups.
Dissolution is slow and depends on the conditions in which it
occurs. Due to the bioavailability of functional groups in
PVM/MA, the covalent binding of molecules with nucleophilic
groups, such as hydroxyls (-OH) or amines (-NH2), occurs by
simple incubation in an aqueous medium.
Non-pegylated nanoparticles of this copolymer and their
preparation are described in NO 02/069938 belonging to the
same applicant. The vinyl methyl ether and
maleic anhydride copolymer nanoparticles are easily prepared
by desolvating the polymer by means of adding to an organic
solution thereof a first polar solvent (miscible with a
solution of the polymer) and subsequently adding a second non-
solvent liquid, in this case a hydroalcoholic solution. A
cross-linking agent can optionally be added. Obtaining
pegylated nanoparticles of this polymer is described below and
it has been found that they are very easy to obtain.
In the present description, the term -polyethylene
glycol" is understood to be any hydrophilic polymer soluble in
water containing ether groups linked by 2 or 3 carbon atom,
optionally branched alkylene groups. Therefore this definition
includes branched or non-branched polyethylene glycols,
polypropylene glycols, and also block or random copolymers
including the two types of units. The term also includes
=
CA 02564982 2006-10-27
12
derivatives of the terminal hydroxyl groups, which can be
modified (1 or both ends) so as to introduce alkoxy, acrylate,
methacrylate, alkyl, amino, phosphate, isothiocyanate,
sulfhydryl, mercapto and sulfate groups. The polyethylene
glycol or polypropylene glycol can have substituents in the
alkylene groups. If they are present, these substituents are
preferably alkyl groups.
Polyethylene glycols are water-soluble polymers that
have been approved for the oral, parenteral and topical
administration of drugs (FDA). Polyethylene glycols are
produced by means of polymerization of ethylene oxide (EO) or
propylene oxide (PO) in the presence of water, monoethylene
glycol or diethylene glycol as reaction initiators in an
alkaline medium (1,2-Epoxide Polymers: Ethylene Oxide Polymers
and Copolymers" in Encyclopedia of Polymer Science and
Engineering; Mark, H.F. (Ed.), John Wiley and Sons Inc., 1986,
pp. 225-273). When the desired molecular weight (generally
controlled by means of in-process measurements of viscosity)
is reached, the polymerization reaction ends by neutralizing
the catalyst with an acid (lactic acid, acetic acid or the
like). The result is a linear polymer having a very simple
structure:
HO - (CH2-CH2-0), - H
where (n) is the number of EO monomers or units. The
units alternatively contain propylene groups.
Although technically all these products should be called
poly(oxyalkylenes), products with mean molecular weights (or
molecular mass) between 200 and 35,000 are known as
polyethylene glycols (PEGs). This term polyethylene glycol is
normally used to indicate the significant influence of
hydroxyl terminal groups on the physicochemical properties of
these molecules. The term PEG is normally used in combination
with a numerical value. In the pharmaceutical industry the
CA 02564982 2006-10-27
13
number indicates the mean molecular weight, whereas in the
cosmetic Industry the number accompanying the letters PEG
refers to the polymerized EO units forming the molecule (Hand
book of Pharmaceutical Excipients, Rowev R.C., Sheskey P. J.,
Weller P.J. (Eds.), 4th Edition, Pharmaceutical Press and
American Pharmaceutical Association, London, UK, 2003). PEGs
are included in various pharmacopeias, although the
nomenclature differs (International
Harmonisation:
Polyethylene glycol (PEG): Pharmeuropa 1999, 11, 612-614).
According to the Handbook of Pharmaceutical Excipients (Fourth
Edition), 2003 Edited by R.C. Rowe, P.J. Sheskey and P.J.
Weller Published by the Pharmaceutical Press (London, UK) and
the American Pharmaceutical Association (Washington, USA),
polyoxyethylene glycols are also referred to as polyethylene
glycols, macrogols, macrogol or PEG. The British Pharmacopoeia
uses polyethylene glycols and macrogols, the Ph Eur
polyethylene glycols and macrogol while the US pharmacopoeia
(USP) uses polyethylene glycol(s).
PEGs with molecular weight less than 400 are non-
volatile liquids at room temperature. PEG 600 shows a melting
point comprised between 17 and 22 C, whereas PEGs with mean
molecular weights comprised between 800 and 2000 are pasty
materials with low melting points. Above a molecular weight
exceeding 3000, PEGs are solid and up to PEG 35000 is
commercially available. On the other hand, although the
melting point of PEGs increases when the molecular weight
increases, the boiling point increases up to a maximum value
of 60 C. Likewise, when the molecular weight increases, its
aqueous solubility decreases. In any case for PEG 35000, an
amount close to 50% m/m can be dissolved in water.
From a toxicological point of view, PEGs are considered
rather non-toxic and non-immunogenic (Hermansky S.J et al.,
Food Chem. Toxic., 1995, 33, 139-140; Final Report on the
Safety Assessment of PEGs: J.A. C. T., 1993, 12, 429-457;
Polyethylene glycol, 21 CFR 172.820, FDA). The allowable daily
CA 02564982 2006-10-27
14
intake defined by the WHO is 10 mg/kg weight (Polyethylene
glycols; Twenty-third report of the Joint FAO/WHO Expert
Committee on Food Additives; World Health Organisation,
Geneva; Technical Report Series 1980, 648, 17-18).
Polyethylene glycol derivatives have advantages that are
similar to traditional PEGs such as their aqueous solubility,
physiological inactivity, low toxicity and stability under
very different conditions. These derivatives include very
different products and are characterized by the functional
group substituting the hydroxyl, such as -NH2 (among the most
reactive ones), phenol, aldehyde, isothiocyanate, -SH groups,
etc. The following can be pointed out among the polyethylene
glycol derivatives that can be used in the invention:
- Polyoxyethylene esters: PEG
monomethyl ether
monosuccinimidyl succinate ester; PEG monomethyl ether
monocarboxymethyl ether; PEG adipate; PEG distearate; PEG
monostearate; PEG hydroxystearate; PEG dilaurate; PEG
dioleate, PEG monooleate, PEG monoricinoleate; PEG coconut oil
esters.
- Polyoxyethylene alkyl ethers: PEG monomethyl ether or
methoxy PEG (mPEG); PEG dimethyl ether.
- Others: Poly(ethylene glycol terephthalate); polyoxyethylene
derivatives and sorbitan esters and fatty acids; ethylene
oxide and propylene oxide copolymers; ethylene oxide with
acrylamide copolymers.
- PEG derivatives: 0,0 -Bis-(2-aminoethyl)polyethylene glycol
(DAE-PEG 2000); 0,0 -Bis-(2-aminopropyl)polypropylene glycol-
polyethylene glycol-polypropylene glycol.
In one variant of the invention the polyethylene glycol
is not branched and does not have substituted hydroxyl groups.
In this variant the polyethylene glycols used preferably have
a molecular weight between 400 and 35,000 Da. When the
molecular weight is less than 400 Da it has been found that
pegylation does not efficiently occur. Therefore in one
preferred variant of the invention the polyethylene glycol
CA 02564982 2006-10-27
used in manufacturing pegylated nanoparticles has a molecular
weight equal to or greater than 400, more preferably equal to
or greater than 1000, values between 1500 and 10,000 are
especially preferred, preferably between 2000 and 5000 KDa.
5 Therefore, in one variant of the invention polyethylene
glycol 2000 (PEG 2000) is used. The amount PEG 2000 with
respect to the polymer is preferably from 1:2-6, values close
to a 1:4 ratio provide good results. For example about 0.25 mg
PEG 2000/mg polymer provides efficient pegylation. In this
10 case, the amount associated to the nanoparticles is about 55.0
micrograms per mg nanoparticle. These nanoparticles are
characterized by having a spherical shape and a size close to
300 nm.
In another variant of the invention the polyethylene
15 glycol used in manufacturing pegylated nanoparticles has a
blocked terminal hydroxyl group, for example by means of a
methyl ether derivative. This reduces its hydrophilia and can
even change the structure of the nanoparticle. In this case, a
greater percentage of the polyethylene glycol chains would be
included inside it and only a small part thereof would be
located on the surface of the nanoparticles. This
particularity allows us to modulating the features of the
nanoparticles by means of blocking the hydroxyl groups or by
introducing other functional groups as described below. In the
case of m-PEG, which is inside the nanoparticles, its function
would be to modify the release of the drug by modifying the
porosity of the polymeric matrix.
Polyethylene glycol methyl ether 2000 (mPEG 2000) is
used in a preferred variant. The amount of mPEG 2000 with
respect to the polymer is preferably 1:2-6, values close to a
1:4 ratio provide good results, for example, about 0.25 mg
mPEG 2000/mg polymer. In this case the amount associated to
the nanoparticles is 35.5 micrograms per mg nanoparticle.
These nanoparticles are characterized by having a spherical
shape and a size close to 300 nm.
CA 02564982 2006-10-27
16
In another variant of the invention the polyethylene
glycol used has terminal functional groups different from the
hydroxyl group, such as amino groups. These amino groups can
in turn be substituted and have functional groups. In a
preferred variant the amino groups are -NH2. It has been
observed that with these groups, the oral administration of
the nanoparticles accumulate on certain segments of the
intestinal tract, which allows a specific administration.
Therefore, in one variant the polyethylene glycol used
in manufacturing pegylated nanoparticles is 0,0-bis-(2-
aminoethyl)polyethylene glycol 2000 (DAE-PEG 2000). In this
case it is though that the structure of the pegylated
nanoparticle is not the "brush" type structure because the
chains would be joined at the two ends, giving rise to a
"loop" type shape. The amount of DAE-PEG with respect to the
polymer is preferably less than 1:4. In a preferred variant it
is equal to or less than 0.25 mg DAE-PEG 2000/mg polymer. In
this case the amount associated to the nanoparticles is about
90.6 micrograms per mg nanoparticle. These nanoparticles are
characterized by having a spherical shape and a size close to
500 nm.
In another variant the polyethylene glycol used in
preparing the pegylated nanoparticles has amino groups and
branches in the alkyl group. It has been found that with these
substituents the trend is to form a brush-type structure, with
one of the ends inside the nanoparticle and the other one on
the outside.
Therefore if the polyethylene glycol used is 0,0'-bis-
(2-aminopropyl)polypropylene glycol-polyethylene
glycol-
polypropylene glycol 2000 (DAP-PEG 2000) the nanoparticles are
characterized by having a spherical shape and a size close to
360 nm. In this case the amount of DAP-PEG with respect to the
polymer is preferably equal to or less than 0.25 mg DAP-PEG
2000/mg polymer), the amount associated to the nanoparticles
is 67.6 micrograms per mg nanoparticle.
CA 02564982 2006-10-27
17
The chemical structures of some of polyalkylene glycols
corresponding to the previously mentioned groups with
different types of functional groups are illustratively
provided below:
a) H(OCH2CH2)flOH
b) H3C(OCH2CH2)õOH
c) H2N(CH2CH20),,CH2CH2NH2
d) H2NCHCH3CH2(OCHCH3CH2) (OCH2CH2).(OCH2CHCH3)NH2
Specific examples would be:
a) polyethylene glycol 400, 1000 or 2000 (PEG 400, PEG 1000 or
PEG 2000);
b) polyethylene glycol methyl ether 2000 (mPEG 2000);
C) 0,0'-Bis-(2-aminoethyl)polyethylene glycol 2000
(DAE-PEG
2000);
d) 0,0'-Bis-(2-aminopropyl)polypropylene glycol- polyethylene
glycol-polypropylene glycol (DAP-PEG 2000);
As can be seen from the foregoing, which is confirmed by
the examples, the selection of the type of polyethylene glycol
allows modulating at will the features of the system which is
generated. The use of mixtures of different types of
polyethylene glycols adds an additional variability factor.
From the practical point of view, this is important for
adapting and selecting the most suitable system for each
active molecule and for each administration method.
The process of preparing the biodegradable polymer and
polyethylene glycol nanoparticles, preferably vinyl methyl
ether and maleic anhydride (PVM/MA) copolymer and polyethylene
glycol, is based on the solvent displacement method described
in WO 02/069 938 for example.
In one variant of the invention, the pegylated
nanoparticles are prepared by two different processes: (i)
simultaneous incubation of the two polymers (for example
PVM/MA and PEG) in the organic phase and (ii) incubation of
the biodegradable polymer nanoparticles with an aqueous
solution of polyethylene glycol. These processes are valid for
CA 02564982 2006-10-27
18
preparing PVM/MA nanoparticles with the PEG association on
their surface. The first variant (simultaneous incubation of
polymers) is preferred because it provides a good degree of
association of the PEG.
The first process includes simultaneously dissolving the
biodegradable polymer and the polyethylene glycol in an
organic solvent, such as acetone for example. The incubation
of the mixture is carried out under stirring at room
temperature for a certain time period. The concentration of
the biodegradable polymer is preferably comprised between
0.001 and 10% w/v and the concentration of the polyethylene
glycol or a derivative thereof between 0.001 and 5% w/v.
A certain volume of a polar solvent miscible with the
solution of the polymers, such as ethanol for example, is
optionally added to this solution.
A cross-linking agent can also optionally be used to
improve the stability of the nanoparticles, as described in WO
02/069938. Among the cross-linking agents that can be used are
diaminated molecules (for example 1,3 diaminopropane),
polysaccharides or single saccharides, proteins, and generally
any molecule having functional groups that are able to react
with the Gantrez anhydride groups. In the process of the
invention, cross-linking is not necessary when the PEGs are
added because this occurs simultaneously. A very small amount
of the indicated products must be added if cross-linking them
is desired.
Finally a similar volume of a second non-solvent liquid
is added, preferably a hydroalcoholic solution. In one variant
pharmaceutical grade water is used (purified water of WFI,
according to the application). The organic
phase/hydroalcoholic solution ratio is preferably comprised in
the range of 1/1-1/10. The nanoparticles are formed instantly
in the medium with an appearance of a milky suspension.
The organic solvents are removed by any suitable
process, such as evaporation under reduced pressure, the
CA 02564982 2006-10-27
19
nanoparticles remaining in a stable aqueous suspension.
The nanoparticles are purified by conventional means,
such as centrifugation, ultracentrifugation, tangential
filtration or evaporation, including the use of a vacuum.
Finally, they can be lyophilized if desired for their
long-term storage and preservation. Common cryoprotective
agents such as sucrose or mannitol can be used to facilitate
lyophilization preferably at a concentration comprised between
0.1 and 10% by weight.
The second process includes dissolving the biodegradable
polymer in an organic solvent such as acetone. Pi certain
volume of hydroalcoholic solution such as ethanol and finally
a similar volume of water are subsequently added to this
solution. The nanoparticles form instantly in the medium with
an appearance of a milky suspension. The organic solvents are
removed as described in the previous process, for example by
evaporation under reduced pressure, the nanoparticles
remaining in a stable aqueous suspension. Then the
nanoparticles are incubated in an aqueous solution of
polyethylene glycol. Incubation is carried out with stirring
for a certain time period. The nanoparticles are subsequently
purified by centrifugation and are finally lyophilized using
the same processes described above.
The invention is also aimed at pharmaceutical
compositions comprising the described pegylated nanoparticles
and optionally an active molecule. Suitable pharmaceutical
preparations are those known by a person skilled in the art
for enteral formulations, preferably oral and parenteral
formulations such as infusions, and topical formulations such
as ophthalmic formulations. The formulations shall comprise
the suitable excipients for each formulation. For example, in
the case of oral formulations in tablet or capsule form,
binders, disintegrating agents, lubricating agents, filler
agents, enteric coating, etc., will be included if needed. The
oral formulations are prepared conventionally by mixing, dry
CA 02564982 2006-10-27
or wet granulation and incorporating the pegylated
nanoparticles of the invention.
In one aspect of the invention the pegylated
nanoparticles are administered by a route providing access to
5 a mucosa
of the organism (including oral, rectal, nasal,
vaginal and ocular administration).
When the pegylated nanoparticles are administered
parenterally, they are used to modify the distribution of the
associated biologically active molecule and/or of the
10
conventional nanoparticles. In the case of parenteral
formulations, sterile suspensions or a lyophilizate of the
nanoparticles and a reconstitution carrier, such as a
physiological saline solution, are used. Excipients such as
cryopreserving agents, pH regulating solutions and surfactants
15 can be incorporated if needed.
The described pegylated nanoparticles and their
formulations can be used as a basis for the administration of
biologically active molecules. An active molecule is
understood to be any chemical compound administered to a
20 subject,
preferably a human being, for prophylactic or
therapeutic purposes. Of course the term also includes
macromolecular compounds such as proteins, peptides, nucleic
acids, etc. The pegylated nanoparticles are used to modify the
distribution of the associated biologically active molecule.
In one variant the active molecule is from the group
formed by DNA, RNA, nucleosides, nucleotides, oligonucleotides
or polynucleotides. In another variant the active molecule is
from the protein or peptide groups.
Active molecules from the groups formed by anti-tumor
agents or antigenic agents for tumors, from the groups formed
by protective agents of the central nervous system or
glucocorticoids, etc., can be incorporated. Alternatively, the
active molecule is an antigen for vaccination or an allergen
for immunotherapy.
In one variant of the invention the pegylated
CA 02564982 2006-10-27
21
nanoparticles can also be used as vaccine adjuvants.
The incorporation of the drug to the nanoparticles of
the invention can be done as described in WO 02/069938, by
incorporation to the polymer solution before nanoparticle
formation, or by subsequently adding it to the aqueous
suspension of the already formed nanoparticles. For example,
and depending on the nature of the drug, the following process
can be used:
a) Hydrophobic drugs: addition to the organic phase (acetone)
and joint incubation / solubilization with PVMMA and PEG for a
variable time period (up to 1 hour) with stirring (mechanical,
magnetic or ultrasonic stirring).
b) Hydrophilic drugs: addition to the organic phase (acetone)
and joint Incubation with PVMMA and PEG for a variable time
period (up to 1 hour) with stirring (mechanical, magnetic or
ultrasonic stirring) until obtaining a thin acetone
suspension. This process has been successfully used to
encapsulate a protein model (ovalbumin, protein of about 44
kDa). The incorporation was efficient, allowing elevated
encapsulation of the protein model.
c) Hydrophilic drugs: Addition in the aqueous phase to
incubate with the pre-formed nanoparticles (this is the case
used to encapsulate two fluorescent markers used in the
examples: FITC and RBITC).
The invention is described below by means of several
non-limiting and illustrative examples of the invention.
EXAMPLES
Several techniques have been used for the
physicochemical characterization of the new nanoparticles. The
size and zeta potential of the nanoparticles are determined in
a Zetamaster apparatus (Malvern, United Kingdom). The shape of
the nanoparticles can be observed by electron transmission
microscopy (Zeiss, Germany) after marking the samples with
phosphotungstic acid.
Example 1:
CA 02564982 2006-10-27
22
Preparing pegylated nanoparticles with polyethylene glycol
2000 (PEG - NP)
Two processes have been tested:
-mixing the two polymers in the organic phase
-coating the pre-formed nanoparticles with PEG
The yields of the process for manufacturing the
pegylated nanoparticles are obtained by means of determining
their weight at the end of the process and after their
lyophilization. The manufacturing yields are expressed in
percentages, calculated with respect to the initial mass of
the PVM/MA-copolymer and of polyethylene glycol. The amount of
polyethylene glycol associated to the nanoparticles is
determined by colorimetry (Labsystems iEMS Reader ME), and is
calculated as a difference between the initial amount used and
the amount found in the supernatants obtained during the
preparation of nanoparticles.
1.1. Association of polyethylene glycol to vinyl methyl ether
and maleic anhydride copolymer in the organic phase
This process is carried out by simultaneous incubation
of PVM/MA and PEG 2000 in the organic phase.
To that end, 100 mg of PVM/MA are dissolved in 5 ml of
organic solvent (acetone). Then PEG 2000 is added to this
solution (10 - 50 mg). The mixture is left to react with
magnetic stirring for 1 hour. Then 10 ml of ethanol and 10 ml
of distilled water are added to this phase. The resulting
mixture is left to homogenize for 5 minutes. The organic
solvents are removed by evaporation under reduced pressure
(Buchi R-144, Switzerland), concentrating the suspension of
nanoparticles formed. The suspension is subjected to
purification by centrifugation (20 minutes at 17000 rpm,
twice) (Sigma 3K30, Germany). The supernatants are collected
for analytical assessments whereas the residue is resuspended
in a sucrose aqueous solution (5% w/v). The nanoparticle
suspension is finally frozen and lyophilized in a Genesis 12EL
apparatus (Virtis, USA).
CA 02564982 2006-10-27
23
The obtained nanoparticles have a spherical shape
similar to conventional nanoparticles (Figure 1 b). The
properties of these pegylated nanoparticles are included in
Table 1. The association of PEG 2000 to the nanoparticles
causes an increase in the polydispersion of the population. It
was observed that with an increase in the amount of
polyethylene glycol (1:2 ratio), the size and especially the
polydispersion become very high. The observations of surface
potential of the nanoparticles show lower negative values for
the pegylated nanoparticles. These results suggest the
presence of the polyethylene glycol chains in the surface of
the nanoparticles. It must finally be indicated that with PEG
2000 : PVM/MA ratios of less than 1:4 w/w, the amount of PEG
associated to the nanoparticles is maintained constant and
close to 50 g/mg.
Table 1. Influence of the amount of PEG 2000 on the
physicochemical characteristics of the nanoparticles. The data
express the media S.D. (n=3).
Amount of PEG
PEG 2000
Size Polydispersion Zeta 2000
(mg) (nm) potential ( g/ mg)*
(my)
0 289 11 0.101 - 33.5
6.6
10 317 5 0.218 - 7.8 + 44.9 15.8
0.5
25 299 22 0.210 - 14.6 + 55.0 12.0
0.3
50 400 35 0.570 - 16.3 128.2 86.6
10.0
* Amount of PEG 2000 associated to the nanoparticles
(expressed as g PEG / mg nanoparticles) according to the
colorimetric method.
1.2. Association of polyethylene glycol to the pre-formed
CA 02564982 2006-10-27
24
nanoparticles
100 mg of PVM/MA are dissolved in 5 ml of organic
solvent (acetone). Then 10 ml of ethanol and 10 ml of
distilled water are added to this solution with stirring. The
resulting mixture is left to homogenize for 5 minutes. Then
the nanoparticle suspension is evaporated under reduced
pressure until both solvents are eliminated. The aqueous
nanosuspension volume is adjusted with water to 5 ml and 5 ml
of an aqueous solution containing between 10-25 mg of PEG 2000
are added. The incubation of the nanoparticles in the
polyethylene glycol phase is carried out with magnetic
stirring for 1 hour. The suspension is subjected to
purification by centrifugation (20 minutes at 17000 rpm,
twice) (Sigma 3K30, Germany). The supernatants are removed and
the residue is resuspended in a sucrose aqueous solution (5%
w/v). The nanoparticle suspension is finally frozen and
lyophilized in a Genesis 12EL apparatus (Virtis, USA).
The amount of polyethylene glycol associated to the
nanoparticles is determined by the previously indicated
colorimetric method. The results show that by this process,
the amount of PEG associated to the nanoparticles is
considerably lower than by the process described in Example
1.1 (incubation in the organic phase) (Figure 2). The reason
for this result is the high affinity of polyethylene glycol
for water, therefore an effective association with the
carboxylic groups coming from the hydrolysis of the copolymer
in the pre-formed particles is not obtained. It can be
concluded that the method of obtaining pegylated nanoparticles
by simultaneous incubation of the copolymer and polyethylene
glycol in an organic phase is more efficient than the simple
coating of the pre-formed nanoparticles with PEG.
1.3. Influence of the molecular weight of PEG on the
physicochemical characteristics of pegylated nanoparticles
The process is carried out by simultaneous incubation of
PVM/MA and the desired polyethylene glycol (PEG 400, PEG 1000
CA 02564982 2006-10-27
or PEG 2000) as described in Example 1.1.
To that end, 100 mg of PVM/MA are dissolved in 5 ml of
organic solvent (acetone). Then 25 mg of PEG (400, 1000 or
2000) are added. The mixture is left to react with magnetic
5 stirring for 1 hour. Then 10 ml of ethanol and 10 ml of
distilled water are added to this phase. The resulting mixture
is left to homogenize for 5 minutes. The organic solvents are
removed by evaporation under reduced pressure (Buchi R-144,
Switzerland), concentrating the nanoparticle suspension. The
10 suspension is subjected to purification by centrifugation (20
minutes at 17000 rpm, twice) (Sigma 3K30, Germany). The
supernatants are removed and the residue is resuspended in a
sucrose aqueous solution (5% w/v). The nanoparticle suspension
is finally frozen and lyophilized in a Genesis 12EL apparatus
15 (Virtis, USA).
The amounts of PEG (400, 1000 or 2000) and mPEG 2000
(Example 2) are determined by colorimetric assessment. To that
end, 15 tl of an iodine solution (10 mg/ml of iodine; 20 mg/ml
of potassium iodide) are added to 1 ml of the supernatants
20 obtained during the nanoparticle purification step. The
absorbance of the complex obtained between PEG (or mPEG) and
iodine is observed by colorimetry at X, 540 nm (Sims & Snape,
Anal. Biochem., 107 (1980) 60-63).
Table 2 shows the Influence of the molecular weight of
25 PEG on the physicochemical characteristics of the obtained
nanoparticles. Due to these results, it can be concluded that
low molecular weight polyethylene glycols are not suitable for
pegylation of these nanoparticles. In the case of PEG 400,
which is liquid, association cannot be obtained, and in the
case of PEG 1000, the association is very low. These results
are also confirmed from the study of the surface charge of the
particles. The zeta potential of the nanoparticles modified
with PEG 400 or PEG 1000 is always more negative than that of
the particles pegylated with PEG 2000, and is similar to that
of the non-coated particles. It can be concluded that
CA 02564982 2006-10-27
26
pegylation with PEG 2000 is much more efficient.
Table 2. Influence of the molecular weight of PEG on the
physicochemical characteristics of the pegylated nanoparticles
(PEG/PVM-MA ratio = 0.25). The data express the mean S.D.
(n=3).
Amount g PEG / mg Size Zeta
Type of
nanoparticl nanoparticles (nm)
potential
es Colorimetry H - NMR (mV)
NP* 289 -
33.5
11 6.6
PEG 400 - ND** ND** 241 6 -
40.1
NP 1.5
PEG 1000 - ND** 19.8 271 + -
45.3
NP 10 5.0
PEG 2000 - 55.0 + 12.0 30.2 299 -14.6
+
NP 22 0.3
* NP - nanoparticles not treated with PEG
** ND - not detectable
Determination of the amount of PEG associated to the
nanoparticles by nuclear magnetic resonance (method described
in Example 5).
Example 2:
Preparing pegylated nanoparticles with polyethylene glycol
methyl ether 2000 (mPEG-NP)
This process is carried out by simultaneous incubation
of PVM/MA and mPEG in an organic phase.
To that end, 100 mg of the copolymer PVM/MA are
dissolved in 5 ml of organic solvent (acetone). Then, an
amount of mPEG 2000 is added to this solution (10 - 50 mg).
The mixture is left to react with magnetic stirring for 1
hour. Then, 10 ml of ethanol and 10 ml of distilled water are
added to this phase. The resulting mixture is left to
homogenize for 5 minutes. The organic solvents are removed by
CA 02564982 2006-10-27
27
evaporation under reduced pressure (Buchi R-144, Switzerland),
concentrating the nanoparticle suspension. The suspension is
subjected to purification by centrifugation (20 minutes at
17000 rpm, twice) (Sigma 3K30, Germany). The supernatants are
removed and the residue is resuspended in a sucrose aqueous
solution (5% w/v). The nanoparticle suspension is finally
frozen and lyophilized in a Genesis 12EL apparatus (Virtis,
USA).
Figure 1(c) shows that the nanoparticles coated with
mPEG 2000 have a spherical shape and the surface seems to be
smooth. Table 3 shows the level of association of mPEG 2000 to
the nanoparticles and their influence on size, polydispersion
and surface charge of the nanoparticles. The results show that
with an increase in the initial amount of mPEG 2000, the
percentage associated to the nanoparticles slightly increases.
The presence of mPEG increases polydispersion of the
nanoparticle population, especially at a high concentration
(mPEG/PVM-MA ratio greater than 0.25). On the other hand, the
negative charge of the nanoparticles decreases when the amount
of mPEG used increases. However, the considerable deviations
observed when high amounts of mPEG are used suggest that the
surface distribution of the mPEG 2000 chains is not
homogenous.
CA 02564982 2006-10-27
28
Table 3. Influence of the amount of mPEG 2000 on the
physicochemical characteristics of the nanoparticles. The data
express the mean S.D. (n=3).
mPEG 2000 Amount
Size Polydispersion Zeta mPEG
2000
(mg)
(nm) potential ( g/
mg)*
(my)
0 289 11 0.101 - 33.5 6.6
254 9 0.128 - 19.7 7.4 36.1 14.3
25 272 17 0.151 - 11.8 2.2 35.5
7.5
50 329 20 0.350 - 21.0 116.8
10.0 68.4
* Amount of mPEG 2000 associated to the nanoparticles
5 (expressed as g mPEG / mg nanoparticles) according to the
colorimetric method.
Example 3:
Preparing pegylated nanoparticles with 0,0'-Bis-(2-aminoethyl)
polyethylene glycol 2000 (DAE-PEG-NP)
10 This process is carried out by simultaneous incubation
of PVM/MA and DAE-PEG 2000 in an organic phase.
To that end, a certain amount of DAE-PEG (5, 10, 25 or
35 mg) is dissolved in 5 ml of organic solvent (acetone). Then
100 mg of PVM/MA are added to this solution with magnetic
stirring. The resulting mixture is left to react with magnetic
stirring for 1 hour. 10 ml of ethanol and 10 ml of distilled
water are added to this organic phase with stirring. The
resulting mixture is left to homogenize for 5 minutes. The
organic solvents are removed by evaporation under reduced
pressure (Buchi R-144, Switzerland), concentrating the
nanoparticle suspension. The suspension is subjected to
purification by centrifugation (20 minutes at 17000 rpm,
twice) (Sigma 3K30, Germany). The supernatants are removed and
the residue is resuspended in a sucrose aqueous solution (5%
w/v). The nanoparticle suspension is finally frozen and
CA 02564982 2006-10-27
29
lyophilized in a Genesis 12EL apparatus (Virtis, USA).
The amount of DAE-PEG and of DAP-PEG (example 4) is
determined after adding the reagent Micro BCATM Protein Assay
Reagent Kit (Pierce, U.S.A.) to the supernatants obtained for
the nanoparticle purification step. This reagent is able to
interact with the amino groups of these polyethylene glycols
giving a colored complex. To that end, 150 1 of reagent are
added to the same volume of supernatant. Absorbance is
determined by colorimetry at X 570 nm after incubation for two
hours at 37'C.
Figure 1 (d) shows that the nanoparticles coated with
DAE-PEG 2000 have a spherical shape. The Table 4 shows the
level of the association of DAE-PEG 2000 and its influence on
size, polydispersion and surface charge of the nanoparticles.
The results show that increasing the amount of GAS-PEG 2000
(from 5 to 35 mg) increases the amount of excipient attached
to the nanoparticles. However, when the amount of DAE-PEG 2000
used is greater than 25 mg, the nanoparticles are not formed.
When analyzing the size, it is observed how increasing
the degree of association produces nanoparticles with a larger
size and greater polydispersion. Therefore, when the DAE-PEG
nanoparticles are produced with 25 mg, the resulting particles
have a size greater than 500 nm and very high polydispersion.
On the other hand, a reduction in the negative surface charge
of the coated nanoparticles in comparison with the non-coated
nanoparticles is observed. These data suggest that the DAE-PEG
2000 chains are present in the surface of the nanoparticles.
CA 02564982 2006-10-27
Table 4. Influence of the amount of DAD-PEG on the
physicochemical characteristics of the nanoparticles. The data
express the mean S.D. (n=3).
DAD-PEG Amount
Size (nm) Polydispersion Zeta potential DAD-PEG
(mg)
(mV) (
g/ mg)*
0 289 11 0.101 - 33.5 6.6
5 324 14 0.207 -14.0 9.0
27.0 7.0
10 387 23 0.296 - 11.9 3.5
71.1 24.0
25 505 88 0.946 - 5.5 1.5
90.6 6.0
* Amount of DAE-PEG 2000 associated to the nanoparticles
5 (expressed as g DAD-PEG / mg nanoparticles) according to the
calorimetric method.
Example 4:
Preparing pegylated nanoparticles with 0,0'-Bis-(2-
aminopropy1)-polypropylene glycol-
polyethylene glycol-
10 polypropylene glycol 2000 (DAP-PEG-NP)
This process is carried out by simultaneous incubation
of PVM/MA and DAP-PEG 2000 in an organic phase.
To that end, a certain amount of DAP-PEG 2000 (10-50 mg)
is dissolved in 5 ml of organic solvent (acetone). Then 100 mg
15 of the vinyl methyl ether and maleic anhydride copolymer are
added to this solution with magnetic stirring. The resulting
mixture is left to react with magnetic stirring for 1 hour.
Then 10 ml of ethanol and 10 ml of distilled water are added
to this phase with stirring. The resulting mixture is left to
20 homogenize for 5 minutes. The organic solvents are removed by
evaporation under reduced pressure (Buchi R-144, Switzerland),
concentrating the nanoparticle suspension. The suspension is
subjected to purification by centrifugation (20 minutes at
17000 rpm, twice) (Sigma 3K30, Germany). The supernatants are
25 removed and the residue is resuspended in a sucrose aqueous
solution (5% w/v). The nanoparticle suspension is finally
frozen and lyophilized in a Genesis 12EL apparatus (Virtis,
CA 02564982 2006-10-27
31
USA).
Figure 1 (e) shows that the nanoparticles coated with
DAP-PEG 2000 have a spherical shape and a smooth surface.
Table 5 shows the general characteristics of these
nanoparticles. The results show that increasing the amount of
DAP-PEG 2000 increases its amount attached to the
nanoparticles. However, when the amount of DAP-PEG 2000 used
is greater than 35 mg, the nanoparticles are not formed.
It is observed that increasing the degree of association
produces nanoparticles with a larger size and also greater
polydispersion. The observations of the zeta potential show a
significant reduction of the negative values obtained for the
coated nanoparticles (values close to zero). These results
suggest that the DAP-PEG 2000 chains are preferably located in
the surface of the nanoparticles.
Table 5. Influence of the amount of DAP-PEG 2000 in the
physicochemical characteristics of the nanoparticles. The data
express the mean S.D. (n=3).
DAP- PEG Amount
Size (nm) Polydispersio Zeta DAP-PEG
42g0
potential (
g/ mg)*
(mV)
0 289 11 0.101 - 33.5 6.6
10 347 7 0.089 - 4.1 1.7 ND**
25 361 15 0.169 - 2.7 0.8 67.6 17.6
35 512 12 0.372 - 6.9 0.7 101.1 11.9
* Amount of DAP-PEG 2000 associated to the nanoparticles
(expressed as lug DAP-PEG / mg nanoparticles) according to the
colorimetric method.
** ND - not detectable
Example 5:
Study of the yield of the process and of the structure of the
pegylated nanoparticles
CA 02564982 2006-10-27
32
Figure 3 shows the influence of the type of polyethylene
glycol in the percentage of PVM/MA transformed into
nanoparticles, and in the total yield of the process. In
general the percentage of copolymer transformed into
nanoparticles is close to 73%. It is observed that when the
nanoparticles are modified with PEG or mPEG, the percentage of
PVM/MA transformed into particles is not significantly
modified. However, nanoparticle pegylation with DAE-PEG or
DAP-PEG decreases the process yield.
The association of polyethylene glycols to the
nanoparticles is confirmed by the element analysis method
(Leco CHN-900, U.S.A.). According to this technique, they may
show changes in their oxygen, hydrogen or nitrogen composition
when associated to other components (for example: PEG).
Table 6 includes the C, H, 0 and N element composition
of the different types of pegylated nanoparticles. Compared
with conventional nanoparticles (NP), all the pegylated
nanoparticles show an increase in the percentage of hydrogen
(H) and a relative decrease in their oxygen content. On the
other hand, DAE-PEG NP and DAP-PEG NP show the presence of
nitrogen which is not observed in the non-modified
nanoparticles.
Table 6. Comparison between the element percentages of
pegylated nanoparticles and non-modified particles (NP).
Percentage (%)
Sample C H 0
NP 51.72 5.24 43.04
PEG - NP 51.39 5.44 43.17
mPEG - NP 52.00 5.47 42.53
DAE-PEG - NP 51.24 5.92 42.69 0.14
DAP-PEG - NP 52.78 5.79 41.10 0.33
The location of the polyethylene glycols (inside or in
the surface of the nanoparticles) is analyzed by nuclear
magnetic resonance ('H-NMR) (Bruker 400 Ultrashield TM,
Germany) after dissolving 5 mg of pegylated nanoparticles in
CA 02564982 2006-10-27
33
0.5 ml of deuterated dimethyl sulfoxide. The spectrums of
pegylated nanoparticles with PEG and mPEG are obtained after
applying 6400 sweeps, whereas the spectrums of DAE-PEG-NP and
DAP-PEG-NP after 12800 sweeps. The spectrums show the typical
hydrogen peak of the polyethylene units (at 3.51 ppm, -
OCH2CH2-) and the hydrogen peaks of the hydroxyl groups (in
the case of PEG and mPEG), or the hydrogen peaks of the amino
groups of DAE-PEG and of DAP-PEG (at 4.58 ppm) (Figure 4). A
ratio of the values of areas of these two peaks is in the
spectrums of the pegylated particles and in the spectrums of
the free polyethylene glycols is calculated. The values of
these ratios can provide Information for locating the
polyethylene glycol chains in the pegylated nanoparticles.
It is observed that the hydrogen peak of the hydroxyl
group (4.58 ppm) appears in the spectrum of the pegylated
nanoparticles with PEG 2000 (Figure 5 a). Table 7 shows the
area of the two previously mentioned peaks (at 3.51 ppm and at
4.58 ppm) and the ratios between them for PEG-NP and free PEG.
It is calculated that the ratio between these two peaks for
nanoparticles is about two times greater than for free PEG
2000. In the case of these nanoparticles these data mean that
the proportion of hydroxyl groups is two times less, therefore
it can be concluded that a significant number of these
functional groups (which do not appear in the spectrum) are
attached to the anhydride groups of the copolymer. According
to these observations, a small part of the PEG 2000 chains
would be included inside the nanoparticles, whereas most of
the PEG chains would be arranged in the surface thereof. This
fact corroborates the zeta potential data shown in Table 1.
Table 7 shows the data referring to the areas of the two
peaks for m-PEG - NP and free mPEG 2000. It is observed that
the ratio between the two peaks for the pegylated
nanoparticles and mPEG 2000 is similar (177 vs. 217). These
results show that the mPEG hydroxyl group proportion in the
two cases (nanoparticles and free mPEG) is similar and that a
CA 02564982 2006-10-27
34
small percentage reacts with the anhydride groups of the
copolymer. It can be concluded that the structure of these
particles is different from that of PEG-NP. In this case, a
greater percentage of mPEG chains would be included inside,
and only a small part thereof would be located in the surface
of the nanoparticles. Therefore the surface distribution of
the mPEG chains is not homogenous, which is consistent with
the large deviations observed in the analysis of the zeta
potential of these particles (Table 3).
Table 7. Analysis of the spectrums of PEG 2000 and pegylated
nanoparticles with PEG 2000 by means of the nuclear magnetic
resonance (H-NMR) method.
Area of the peaks
Peak A Peak B Ratio
Shows 3.51 ppm 4.58 ppm A / B
(hydrogen of the (hydroxyl
polyethylene hydrogen)
units)
PEG 2000 75.35 x 109 73.65 x 107 102.3
PEG - NP 2.03 x 109 1.11 x 107 183.3
mPEG 46.00 x 109 26.01 x 107 176.8
mPEG - NP 2.30 x 109 1.06 x 107 217.0
Table 8 shows the data referring to the areas of the
peaks for DAP-PEG-NP and free DAP-PEG 2000. In the DAP-PEG
2000 spectrum, there are two signals corresponding to
hydrogens of the two different amino groups located at the
ends of its chain: a doublet at 5=4.55 ppm and another one at
5=4.45 ppm (Figure 6 b). It is observed that in the spectrum
CA 02564982 2006-10-27
of the pegylated nanoparticles with DAP-PEG 2000, there is no
hydrogen of these amino groups (Figure 6 a), which indicates
that all the amino groups of this type of polyethylene glycol
react with the anhydride groups of the polymer forming the
5
nanoparticles. Furthermore, the DAP-PEG chains would be
attached to the surface of the nanoparticles at the two end
amino groups and the surface coating would be complete. This
would be supported by the zeta potential values (close to
cero) of these particles (Table 5).
Table 8. Analysis of the spectrums of DAP-PEG 2000 and of the
pegylated nanoparticles (DAP-PEG - NP) by means of the nuclear
magnetic resonance (H-NMR) method.
Area of the peaks
Shows Peak A Peak B Peak C
3.51 ppm 4.55 ppm 4.45 ppm
(hydrogen of the (amino group (amino
polyethylene hydrogen) group
units) hydrogen)
DAP-PEG 115.14 x 109 9.83 x 106 21.46 x 106
DAP-PEG - 9.81 x 109
NP
In the case of DAE-PEG 2000, it is not possible to
calculate the same ratio between the two peaks because the
peak at 4.58 ppm has a very low intensity and low resolution
(independent of the concentration and number of sweeps carried
out) (Figure 7 b). In any case, it can be observed that this
peak appears in the spectrum of the nanoparticles as well as
in the spectrum of DAE-PEG 2000. Therefore, it can be
concluded that part of the DAE-PEG chains would be Included
inside the particles. However, most of them would be located
in the surface attached only at the end of the chain of this
CA 02564982 2006-10-27
36
polyethylene glycol.
With respect to these data, it can be concluded that the
pegylated nanoparticles have a different structure. The
structure proposed for the different formulations is shown in
Figure 8. Certain polyethylene glycols such as PEG 2000, DAB-
PEG and DAP-PEG, modify the surface of the developed
nanoparticles. In the case of PEG-NP and DAB-PEG-NP, the
coating would give rise to a "brush"-type structure (Figure 8
a and c), whereas in the case of DAP-PEG, the chains would be
attached at the two ends giving rise to a "loop"-type
formation (Figure 8 d). The only case in which modification of
the nanoparticle surface is not observed is when mPEG 2000 is
used. mPEG would mostly be found inside the nanoparticles
(Figure 8 b).
Example 6:
Study of the bioadhesive characteristics of pegylated
nanoparticles in the gastrointestinal tract of rats
This study was carried out according to the regulations
of the Ethics Committee of the University of Navarra in
accordance with European laws on experimenting with animals
(86/609/EU).
The pegylated nanoparticles used in this assay are
fluorescently marked with rhodamine B isothiocyanate. To that
end, the nanoparticles are formed by means of simultaneous
incubation of PVM/MA and the different types of polyethylene
glycols (according to the process in Examples 1.1, 2, 3 and
4). Then 10 ml of ethanol and 10 ml of distilled water are
added to this phase with stirring. The resulting mixture is
left to homogenize for 5 minutes. The organic solvents are
removed by evaporation under reduced pressure (Buchi R-144,
Switzerland), concentrating the nanoparticle suspension. The
volume of aqueous nanosuspension is adjusted with water to 9
ml and 1 ml of a rhodamine B isothiocyanate aqueous solution
(1.25 mg/ml) is added. The incubation of the nanoparticles
with the fluorescent marker is carried out with stirring for 5
CA 02564982 2006-10-27
37
minutes. Then the fluorescently modified nanoparticle
suspension is subjected to purification by centrifugation (20
minutes at 17000 rpm, twice) (Sigma 3K30, Germany). The
supernatants are removed and the residue is resuspended in a
sucrose aqueous solution (5% w/v). The nanoparticle suspension
is finally frozen and lyophilized in a Genesis 12EL apparatus
(Virtis, USA).
Table 9 includes the characteristics of the formulations
used in this assay and fluorescently marked with rhodamine B
isothiocyanate.
Table 9. Physicochemical characteristics of the nanoparticles
considered in the bioadhesion study. Mean SD (n=3).
Samples Size Zeta
Polyethylene Rhodamine
(nm) potential glycol (
g/mg)**
(mV) ( g/mg)*
NP 289 11 - 33.5 + 10.33
6.6 0.87
PEG - NP 299 22 - 14.6 55.0 12.0
10.37
0.3 0.09
mPEG - NP 272 17 -11.8 35.5 7.5 10.46
2.2 0.11
DAB-PEG - NP 505 88 - 5.5 90.6 6.0 10.04
1.5 0.62
DAP-PEG - NP 361 + 15 - 2.7 + 67.6 17.6 8.74
+
0.8 0.75
* Amount of polyethylene glycol associated to the
nanoparticles (lig PEG/mg nanoparticles).
** The amount of rhodamine B isothiocyanate attached to
nanoparticles (expressed in [ig/mg nanoparticles) is determined
by colorimetry at 540 nm.
The obtained nanoparticles (10 mg) are orally
administered to male rats (Wistar type, weight 220.0 g) after
their dispersion in 1 ml of water. After the oral
CA 02564982 2006-10-27
38
administration, the animals are sacrificed by cervical
dislocation at different times: 0.5, 1, 3 and 8 hours. The
abdominal cavity is opened and the gastrointestinal tract
extracted. The area is divided into the following anatomical
portions: stomach, small intestine and cecum. Each segment is
longitudinally opened through the mesentery and is washed with
saline phosphate buffer (pH=7.4; 0.15 M) to remove the non-
adhered nanoparticle fraction. Furthermore, each segment is
cut into portions of a length of 2 cm digested for 24 hours
with 1 ml of 3M sodium hydroxide (Arbos et al., Int. J.
Pharm., 242 (2002) 129-136). Then the rhodamine is removed
with 2 ml of methanol and the samples are centrifuged for 10
minutes at 4000 rpm. The supernatants (1 ml) are diluted with
3 ml of water and the amount of rhodamine is determined by
means of fluorescence spectroscopy at ke,, = 540 nm and Xõ,õ = 580
nm (GENios, Austria). The fraction of nanoparticles adhered to
the mucosa can be estimated according to this process.
The specific distribution of the pegylated nanoparticles
in the different parts of the gastrointestinal tract is shown
in Figure 9. All the formulations showed a significant initial
adhesion to the mucosa of the stomach. The percentage of the
dose adhered to this organ 30 minutes after its administration
ranged between 13% for PEG-NP and 9% for DAP-PEG-NP. All the
pegylated nanoparticle formulations also showed a certain
affinity for the 13 portion of the small intestine; however,
PEG-NP and DAE-PEG-NP were shown to be the most efficient
formulations 3 hours after administration for maintaining
amounts adhered to the small intestine, close to 20% of the
dose. Finally, the peak of adhered nanoparticles 8 hours after
the administration was found in the last portion of the small
intestine (for PEG-NP) or in the cecum (for mPEG-NP and DAP-
PEG-NP). A relatively significant fraction (close to 10%) of
nanoparticles adhered to the mucosa could still be quantified
in the case of PEG-NP and DAP-PEG-NP. In conclusion, it can be
asserted that the nanoparticles coated with PEG 2000 and mPEG
CA 02564982 2006-10-27
39
2000 show a very homogenous distribution and are disseminated
on all the parts of the tract for 8 hours (Figure 9 a and b).
The pegylated nanoparticles with DAE-PEG are preferably
adhered in the intermediate portions of the small intestine
(Figure 9 c), whereas the nanoparticles modified with DAP-PEG
2000 accumulate mainly in the distal regions of the intestinal
tract (Figure 9 d). These results mean that the nanoparticles
herein developed can provide a specific drug release.
Bioadhesion parameters (Arbos et al., Int. J. Pharm.,
242 (2002) 129-136): The adhesion curve of each formulation
was obtained by representing the adhered fraction of pegylated
nanoparticles in the gastrointestinal mucosa of rats over
time. The following bioadhesion parameters were calculated
from this curve: AUCadh, kadh and MRTõdh. kadh represents the
elimination rate of the adhered fraction and was calculated
with the aid of the WinNonlin version 1.5 program (Scientific
Consulting, Inc.). AUCadh or area under the curve of
representing the adhered fraction over time (expressed in the
form of the amount of adhered marker with respect to time) was
evaluated by the trapezoid method to t, (the last sampling
point) and allows quantifying the intensity of the bioadhesive
phenomenon. Finally, MRTddh is the mean residence time of the
adhered fraction of nanoparticles and it allows evaluating the
relative duration of adhesive interactions, using the last
sampling point as the limit.
Figure 10 shows the bioadhesive profiles of the
pegylated nanoparticles in the complete gastrointestinal tract
for 8 hours. All the pegylated nanoparticles show bioadhesive
profiles that are different from the profile of the non-
modified particles (NP). The maximum bioadhesion of NP occurs
30 minutes after its oral administration and decreases quickly
thereafter. In contrast, the pegylated nanoparticles generally
have less initial ability to develop bioadhesive interactions.
However, the adhesive ability is maintained for at least 3
hours. Therefore 3 hours after their administration, the
CA 02564982 2006-10-27
amount of nanoparticles adhered to the gastrointestinal mucosa
ranges between 25% of the administered dose for PEG-NP and 16%
for DAP-PEG-NP, in all cases greater than the control (NP). On
the other hand, the profile obtained for PEG-NP is
5 particularly interesting. These nanoparticles show maximum
adhesion 1 hour after their administration (about 32% of the
dose) and 3 hours after their administration, the levels of
particles adhered to the mucosa are similar to initial levels.
In the case of the remaining pegylated nanoparticles, their
10 initial adhesion is maintained for at least 3 hours.
The bioadhesive parameters can provide more details
regarding the adhesive properties of the nanoparticles (Table
10). As previously stated, the initial ability of the
pegylated nanoparticles to interact with the mucosa (Qmax) is
15 lower that it is for the non-coated particles (NP). However,
the bioadhesion area under the curve (AUO,d0 of the pegylated
nanoparticles is higher; this means that the adhesive
intensity is greater. This phenomenon is particularly observed
in the case of PEG-NP, where AUOõth is 1.6-times greater than
20 for NP. Furthermore, all the pegylated nanoparticle
formulations have a lower degree of elimination of the adhered
fraction (kadd and a longer residence time (MRTadO in
comparison with the non-coated particles. Therefore, the DAP-
PEG-NP show slower elimination of the adhered fraction than
25 for conventional particles, suggesting the long-lasting
bioadhesive potential of these nanoparticles. It is observed
that all pegylated nanoparticles show a long residence time
(MRTadj in the gastrointestinal tract. With respect to the
mean residence time of the adhered fraction (MRT )
it is
30 particularly interesting that all the pegylated nanoparticles
show a significantly greater mean residence time than NP.
Therefore, these nanoparticles show residence times comprised
between 17 and 48 minutes greater than conventional particles.
CA 02564982 2006-10-27
41
Table 10. Bioadhesion parameters of the pegylated
nanoparticles calculated according to their distribution in
the complete gastrointestinal tract over time.
Nanoparticles AUC adh rag MRT (h) k adh (h) Q max. (mg)
h)
NP 11.83 2.0 2.77 0.21 0.01 3.64
0.34
PEG-NP 16.19 3.11 0.17 0.01 3.16
2.29 0.57
mPEG-NP 12.91 3.10 0.16 0.05 2.55
6.84 1.17
DAB-PEG-NP 13.49 3.05 0.17 0.02 2.51
1.76 0.50
DAP-PEG-NP 10.90 3.57 0.14 0.10 2.05
5.04 0.47
Example 7:
Viewing the pegylated nanoparticles in the gastrointestinal
mucosa.
The pegylated nanoparticles are viewed in the
gastrointestinal mucosa by means of fluorescence and optical
microscopy. To that end, the pegylated nanoparticles were
marked with fluorescent molecules such as rhodamine B
isothlocyanate (RBITC) and fluorescein isothiocyanate (FITC).
After the oral administration in rats, different portions of
the intestine are collected and washed with saline phosphate
buffer (pH-7.4; 0.15M), as described above.
In the first case, the segments of the intestine
(containing the nanoparticles marked with RBITC) are fixed in
Tissue-Tee O.C.T. medium (Sakura, Holland) and are frozen by
means of dry ice and 2-methyl butane. The segments are then
cut into 5 larn sections in a cryostat (Leica, Germany) at low
temperature (-22 C). The obtained sections are placed on a
slide coated with poly-L-lysine (Sigma, Spain) and observed
CA 02564982 2006-10-27
42
under a fluorescein microscope (Olympus CH-40, Japan).
On the other hand, the intestinal segments (containing
nanoparticles marked with FITC) are fixed in a formalin
solution (4%) for 24 hours. After the fixing, the tissues are
included in paraffin and then cut into 3 m sections. These
sections are placed on a slide coated with Vectabond (Vector
Labs, U.S.A.). Then the obtained sections are deparaffinized,
rehydrated and endogenous peroxydase is blocked by means of
adding a hydrogen peroxide solution (3%) for 10 minutes. Then
the supports are washed with distilled water (5 min), placed
in citrate buffer (pH=6.0; 0.0151), heated in a microwave (15
minutes at maximum power and 15 minutes at minimum power),
washed with water and finally with Tris saline buffer (TBS)
(pH=7.36; NaCl 0.551; 0.05M). To prevent non-specific marking,
the sections are incubated with normal goat serum (1:20, DAKO,
U.S.A.) at room temperature for 30 minutes and then with the
specific anti-serum (1:100 monoclonal anti-FITC, 510878, DAKO,
U.S.A.) at 4 C for 24 hours. After washing with Tris saline
buffer (TBS), the samples are incubated with goat anti-mouse
Ig secondary antibody coupled to Dextrane marked with
peroxydase (room temperature, 30 minutes). The samples are
washed with TBS buffer and the peroxydase activity is
developed with a diaminobenzidine solution. The sections are
weakly contrasted with hematoxylin, dehydrated and mounted in
DPX. The samples are finally viewed under an optical
microscope (Nicon Eclipse E 80051, Japan).
Figure 11 shows the presence of PEG-NP in the small
intestine epithelial cells. The particles are generally
located in the apical compartment of the cells (Figure 11 a),
although certain fractions which have penetrated between cells
of the intestinal epithelium can be observed (Figure 11 b).
Intensive penetration of the nanoparticles in the
enterocytes can be observed by optical microscopy (Figure 12).
As with fluorescein microscopy, distribution in the apical
compartment of the cells is observed. On the other hand,
CA 02564982 2006-10-27
43
Figure 12 b also shows a distribution in the basolateral
compartment. It is observed that some of the nuclei of the
cells include the marker or marked nanoparticles, which allows
assuming that the use of these nanoparticles can be
interesting to promote the delivery to the nucleus of
different biologically active molecules.
Finally, Figure 13 shows the distribution of these
systems in Peyer's patch cells. The observation that these
nanoparticles seem to be concentrated in the area known as the
"dome" of the Peyer's patch is particularly interesting. The
dome is characterized in that it is the area where cells of
the monocyte-macrophage system accumulate. This allows
asserting the interest of these pegylated nanoparticles for
the development of oral vaccines and in immunotherapy.
